The tumor suppressor serine/threonine kinase 11 (STK11 or LKB1) is mutated in 20-30% of patients with non-small-cell lung cancer (NSCLC). Loss of LKB1-adenosine monophosphate-activated protein kinase (AMPK) signaling confers sensitivity to metabolic inhibition or stress-induced mitochondrial insults. We tested the hypothesis that loss of LKB1 sensitizes NSCLC cells to energetic stress induced by treatment with erlotinib. LKB1-deficient cells exhibited enhanced sensitivity to erlotinib in vitro and in vivo that was associated with alterations in energy metabolism and mitochondrial dysfunction. Loss of LKB1 expression altered the cellular response to erlotinib treatment, resulting in impaired ATP homeostasis and an increase in reactive oxygen species. Furthermore, erlotinib selectively blocked mammalian target of rapamycin signaling, inhibited cell growth and activated apoptosis in LKB1-deficient cells. Erlotinib treatment also induced AMPK activation despite loss of LKB1 expression, which was partially reduced by the application of a calcium/calmodulin-dependent protein kinase kinase 2 inhibitor (STO-609) or calcium chelator (BAPTA-AM). These findings may have significant implications for the design of novel NSCLC treatments that target dysregulated metabolic and signaling pathways in LKB1-deficient tumors.
INTRODUCTION
Lung cancer is the leading cause of cancer-related mortality worldwide and is linked to 28% of all cancer-related deaths in the United States. 1 Despite advances in traditional therapeutic strategies involving surgery, ionizing radiation therapy, and chemotherapy, the 5-year survival remains less than 20%. 2 In recent years, it has become clear that non-small-cell lung cancer (NSCLC) has a high frequency of somatically acquired genetic alterations that define critical subsets of tumors with distinct behaviors. 3 An improved understanding of potential vulnerabilities of lung cancer subsets has led to the development of effective targeted therapies for tumors with certain activated oncogenes, 4, 5 but little is known about specific susceptibilities that may derive from the loss of classical tumor suppressor genes, such as LKB1.
LKB1 is a tumor suppressive serine/threonine kinase that activates diverse downstream kinases, thus regulating a variety of cellular phenotypes including metabolism, invasion, proliferation and polarity. 6 LKB1 inactivation occurs in 20-30% of lung adenocarcinomas, 7 and LKB1 deficiency in combination with KRAS mutation leads to an aggressive tumor phenotype at high prevalence in mouse models, surpassing that of KRAS mutation alone. 8 Many of the metabolic regulatory functions of LKB1 are mediated by its interaction with adenosine monophosphateactivated protein kinase (AMPK). LKB1 phosphorylates and activates AMPK, 6 which functions to regulate cellular energy metabolism under conditions of low ATP. 9 AMPK also contributes to inactivation of mammalian target of rapamycin (mTOR) when ATP levels fall, which leads to inhibition of protein synthesis and cell growth. 10 Therefore, loss of LKB1 leads to dysregulation of cellular metabolism and cell growth under conditions of energy stress, 11 resulting in enhanced sensitivity to drug treatments that target bioenergetic pathways. 12 Most lung cancers express the epidermal growth factor receptor (EGFR), and this signaling pathway is the major target of several drugs in the clinic. EGFR tyrosine kinase inhibitors including gefitinib and erlotinib have been shown to suppress oncogenic signaling through downstream pathways such as PI3K-Akt-mTOR and MAPK/extracellular signal-regulated kinase (Mek)-extracellular signal-regulated kinase (Erk). 13 NSCLC tumors with certain activating mutations in EGFR show enhanced sensitivity to these compounds. 14 However, the majority of NSCLC patient tumors possess wild-type EGFR, with only 10-30% harboring a mutant EGFR allele. 15 Although erlotinib has clear therapeutic efficacy in some NSCLC tumors bearing wild-type EGFR 16, 17 and is approved for patients with wild-type EGFR tumors, 18 it is unclear how to best identify which of these patients may benefit from treatment with EGFR-targeted inhibitors. Furthermore, the mechanism by which erlotinib induces selective cell death in wild-type EGFR tumors is not completely known.
In EGFR mutant NSCLC cells, erlotinib causes apoptosis through activation of intrinsic pathways mediated by the induction of BH3-only BIM protein or activation of caspase 3. 19, 20 In these studies, erlotinib treatment was associated with loss of mitochondrial 1 Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, USA; potential, which resulted in mitochondrial-mediated apoptosis. Interestingly, recent studies suggest that LKB1 deficiency causes an accumulation of defective mitochondria and loss of mitochondrial membrane potential, resulting in depletion of hematopoietic stem cells through disruption of mitophagy and mitochondrial homeostasis. 21 Furthermore, the mitochondrial complex I inhibitor phenformin enhanced apoptosis of LKB1-deficient tumor cells by depletion of mitochondrial membrane potential compared with wild-type LKB1-reconstituted cells. 12 Therefore, we hypothesized that erlotinib would be more effective at inducing apoptosis in LKB1-deficient NSCLC cells because of disruption of normal mitochondrial function, even in the presence of wild-type EGFR.
In the present study, we tested whether LKB1-deficient cells were more prone to apoptosis in response to erlotinib treatment, both in vitro and in vivo, in the absence of mutationally activated EGFR. Our data demonstrate enhanced antitumor effects of erlotinib in LKB1-deficient cells that are associated with loss of mitochondrial function and blockage of mTOR signaling. Overall, our findings suggest that the LKB1-deficient molecular phenotype may serve as a predictive marker for erlotinib sensitivity and, if substantiated by further studies, may provide a rationale for the therapeutic use of erlotinib to treat LKB1-deficient NSCLC. This is significant because LKB1 mutations are preferentially found in NSCLC tumors with wild-type EGFR, 22, 23 and thus LKB1 loss may define a novel subset of tumors with enhanced erlotinib sensitivity that is largely distinct from the classical subset possessing targetable EGFR mutations.
RESULTS

LKB1-deficient cells are more sensitive to inhibition of EGFR-PI3K-mTOR signaling
We sought to determine the relative inhibitory effects of erlotinib, as well as other compounds that target the EGFR-PI3K-mTOR signaling pathway, across a panel of NSCLC cell lines that express either wild-type or mutant LKB1. The expressions of LKB1and EGFR were assessed by western blotting in NSCLC cells (Figure 1a ). The NSCLC cells tested have been reported to express wild-type EGFR, 24, 25 and the expression level of phosphorylated EGFR is shown in Figure 1a . Calu-6, H2009 and H358 cells were previously reported to express wild-type LKB1, [26] [27] [28] and we confirmed LKB1 protein expression in these three lines. Next, we asked whether erlotinib could selectively inhibit the viability of LKB1 mutant cells harboring KRAS mutations but with wild-type EGFR. We found that LKB1 mutant cells were more sensitive to erlotinib on average (Figure 1b) . Furthermore, 10 μM of the PI3K inhibitor LY294002 did not reduce viability of LKB1wild-type NSCLC cells, whereas 30-50% inhibition was observed in LKB1 mutant cells. Sensitivity to rapamycin was also exacerbated in LKB1 mutant cells. We further assessed the survival of NSCLC cells using a colony-forming assay where cells were pretreated with inhibitor for 72 h and then grown in inhibitor-free medium for 2 weeks. The colony-forming assay was more capable of detecting differences in viability at low inhibitor concentrations and confirmed the finding that LKB1 mutant cells were more sensitive to inhibition of EGFR-PI3K-mTOR signaling (Figure 1c) . These results suggest that LKB1 loss confers enhanced sensitivity to inhibition of the EGFR-PI3K-mTOR signaling pathway in NSCLC cells harboring wild-type EGFR.
LKB1-deficient transgenic cells exhibit increased sensitivity to erlotinib treatment A549 and H460 cells (both wild-type EGFR and mutant LKB1) were transduced with retroviral constructs to stably express wild-type LKB1 or an empty vector control. Expression of LKB1 and related downstream signaling proteins was verified in these stable transgenic cells (Figure 2a, left) . LKB1 phosphorylates Thr172 in the activation loop of AMPKα 29, 30 and activates AMPK under elevated AMP levels. 31 Activated AMPK subsequently phosphorylates and inhibits acetyl-CoA carboxylase (ACC). Overexpression of LKB1in A549 and H460 resulted in increased basal phosphorylation of AMPKα and its downstream target ACC. Erlotinib inhibited the growth of LKB1-nonexpressing A549 (P o 0.0001) and H460 cells (P o0.005) more than it did the growth of Cell viability was determined using MTT assay. *P o0.005, **P o0.00001, untreated/erlotinib, *P o0.0001, untreated/LY294002 or untreated/rapamycin. Data are mean ± s.e.m. (n = 6). (c) Effects of treatment with erlotinib, LY294002 or rapamycin on colony-forming ability of NSCLC cells. After 72 h treatment with erlotinib, LY294002 or rapamycin, cells were re-plated in 12-well plates at low density. Colonies were counted after 2 weeks of growth. *P o0.0001, untreated/erlotinib, untreated/LY294002, or untreated/rapamycin. Data are mean ± s.e.m. (n = 3). (Figure 2a, right) . Conversely, in stable LKB1-knockdown lines generated from LKB1 wild-type Calu-6 cells, erlotinib induced a more substantial reduction in growth compared with the vector control ( Figure 2b , lower panel). In addition, erlotinib reduced the colony-forming ability of LKB1-knockdown cells more significantly than the vector control ( Figure 2c ). These results suggest that LKB1 deficiency enhances sensitivity to erlotinib by suppressing the viability and tumorigenic potential of NSCLC cells.
LKB1-overexpressing cells
Erlotinib treatment selectively inhibits oxidative metabolism and disrupts energy homeostasis in LKB1-deficient cells We next determined whether erlotinib treatment alters cellular metabolism through analysis of glucose, lactate and oxygen exchange rates. Knockdown of LKB1 in Calu-6 cells caused basal glucose consumption and lactate production to increase significantly compared with vector control cells (Figure 3a , left), consistent with previously published results. 32 Measurement of oxygen consumption rate (OCR) also revealed a twofold increase in basal oxidative metabolism by shLKB1 Calu-6 cells (Figure 3b , upper), which was further confirmed in shLKB1 H358 cells (Supplementary Figure S1A) . Erlotinib treatment reduced specific growth rates of both vector control and shLKB1 Calu-6 cells in a dose-dependent manner without affecting glucose uptake or lactate production (Figure 3a, left) . However, the OCR of shLKB1-expressing Calu-6 and H358 cells was halved by erlotinib treatment (Figure 3b and Supplementary Figure S1A) . Similar results were observed after re-expressing LKB1 in A549 and H460 cells. LKB1 mutant A549 and H460 cells exhibited increased glucose consumption and lactate production compared with LKB1-overexpressing cells (Figure 3a , right and Supplementary Figure S2) . Furthermore, OCR was significantly elevated in LKB1 mutant cells but was reduced > 50% by erlotinib treatment (Figure 3b and Supplementary Figure S1B) . In contrast to its effects on glycolytic metabolism, the effect of erlotinib to reduce OCR was significantly enhanced in the LKB1 mutant lines.
The reduction in OCR by erlotinib treatment was associated with a significant increase in the ADP/ATP ratio in shLKB1-expressing Calu-6 and H358 cells (Figure 3c ). In contrast, the OCR and ADP/ATP ratio of control Calu-6 and H358 cells was not significantly affected by erlotinib. These results indicate that LKB1-deficient cells were not able to maintain their elevated rate of oxidative phosphorylation in the presence of erlotinib treatment, thus leading to ATP depletion. Several recent articles have shown that loss of LKB1 function leads to increased expression of mitochondria-associated genes 23 but also induces defective mitophagy and accumulation of dysfunctional mitochondria.
12,21 Therefore, we hypothesized that mitochondrial impairments may have a role in the response of LKB1-deficient cells to erlotinib treatment.
Erlotinib treatment unmasks mitochondrial defects in LKB1-deficient cells Erlotinib-induced apoptosis is associated with loss of mitochondrial membrane potential in EGFR mutant NSCLC cells. 20 Therefore, we sought to determine whether EGFR wild-type NSCLC cells bearing lossof-function mutations in LKB1 would show similar mitochondrial defects following erlotinib treatment. We measured the effect of erlotinib treatment on mitochondrial potential by using the cationic dye JC-1. Phenformin, a mitochondrial complex Ι antagonist, was applied as a positive control to impair mitochondria. As shown in Figure 4a , following treatment with erlotinib or phenformin, Calu-6 and H358 cells expressing shLKB1 exhibited enhanced dissipation of Δψ m compared with control cells (red to green ratio of JC-1), reflecting impaired mitochondrial membrane integrity. Significantly, the Δψ m of untreated shLKB1 cells was higher than that of vector controls, which is indicative of increased basal mitochondrial activity and is consistent with the elevated OCR of untreated shLKB1 cells (Figure 3b ). Calu-6 cells To confirm the effect of erlotinib to suppress EGFR activation and signaling through downstream pathways, we performed western blot analysis of EGFR, Akt and mTOR phosphorylation in the presence of exogenous EGF (Figure 5b ). EGF treatment stimulated phosphorylation of EGFR and Akt in both control and shLKB1 cells. EGFR phosphorylation was effectively reduced by erlotinib treatment in both cell types, but only shLKB1 Calu-6 cells exhibited reduced phosphorylation of mTOR in response to erlotinib. Therefore, we hypothesized that activation of AMPKα in LKB1-deficient cells might confer sensitivity to erlotinib through inhibition of mTOR signaling. As shown in Figure 5c , erlotinib induced phosphorylation of AMPKα in both control and shLKB1 Calu-6 cells after 24 h, but shLKB1 cells exhibited complete disruption of mTOR pathway signaling following erlotinib treatment. In particular, AMPKα can directly phosphorylate TSC2 at Ser 1387, which is involved in inhibition of mTOR signaling. shLKB1 Calu-6 cells exhibited enhanced phosphorylation of TSC2 (Ser1387) by erlotinib treatment in comparison with control cells. Furthermore, erlotinib decreased phosphorylation of the 70-kDa ribosomal protein S6 kinase (p70S6K1) and 4EBP-1, both downstream effectors of mTOR signaling. Erlotinib treatment reduced phosphorylation of Akt in all cells, but phosphorylated Erk was not changed. These effects of erlotinib on AMPK and mTOR pathway signaling were further confirmed in H358, A549 and H460 cells. For example, shLKB1 H358 cells exhibited enhanced phosphorylation of AMPKα and inhibition of mTOR signaling in response to erlotinib treatment (Supplementary Figure S4A) , whereas LKB1-overexpressing A549 and H460 cells were less Figure S4B) . These results indicate that erlotinib induces phosphorylation of AMPKα in both control and LKB1-deficient cells, but its effect to block mTOR pathway signaling is enhanced in LKB1-deficient cells, resulting in repression of protein synthesis and inhibition of cell growth.
We then asked whether an alternative kinase other than LKB1 could be responsible for erlotinib-induced activation of AMPKα in LKB1-deficient cells. In a previous study, it was shown that AMPKα can become phosphorylated in response to energy stress, even in the absence of functional LKB1, through the action of calcium/ calmodulin-dependent protein kinase kinase β (CaMKKβ). 33 To elucidate the mechanism by which erlotinib treatment can induce phosphorylation of AMPKα in LKB1-deficient cells, we used STO-609, a CaMKKβ inhibitor, and BAPTA-AM, an intracellular calcium chelator. After 24 h of treatment, both STO-609 and BAPTA-AM were able to partially inhibit erlotinib-induced AMPK phosphorylation in shLKB1 Calu-6 cells (Figure 5d ). This partially blocked erlotinib's ability to inhibit mTOR and induce apoptosis in shLKB1 Calu-6 cells. These results indicate that AMPKα activation can be stimulated by erlotinib-induced changes in intracellular ADP/ATP levels and CAMKKβ activity, even in the absence of functional LKB1. This provides a mechanistic explanation for erlotinib's ability to activate AMPKα and suppress mTOR signaling in LKB1-deficient cells.
Erlotinib reduces tumor volume in shLKB1 Calu-6 tumor xenografts Finally, we investigated the in vivo antitumor activity of erlotinib in nude mice bearing control and shLKB1 Calu-6 subcutaneous tumors. As expected, mice bearing shLKB1 Calu-6 tumor xenografts showed the highest tumor volumes (Figure 6a , left panel). Mean tumor volume in mice bearing shLKB1 tumors was significantly reduced at 2-3 weeks of erlotinib treatment, as compared with control-treated mice (Figure 6a, right panel) . No toxic effects (such as severe reduction in body weight) were observed in erlotinib-treated groups. We performed histological analyses of tumor samples by H&E immunohistochemical staining and found clear signs of large necrotic areas in shLKB1 tumor xenografts treated with erlotinib, but not in control xenografts (Figure 6b ). We also collected tissue samples from tumors to determine the in vivo effects of erlotinib treatment on activation of AMPKα, mTOR, p70S6K and cleaved PARP (Figure 6c ). We first detected levels of LKB1 expression in control and shLKB1 Calu-6 tumor tissues from mice. As shown by western blotting, levels of LKB1 protein were highly reduced in shLKB1 Calu-6 xenograft tumors as compared with control tumors. Consistent with in vitro results, erlotinib treatment enhanced AMPK phosphorylation, inhibited mTOR-related downstream signaling proteins and increased PARP cleavage in shLKB1 Calu-6 xenograft tumors only. These results suggest that erlotinib treatment significantly reduced tumor growth in shLKB1 Calu-6 tumor xenografts through inhibition of mTOR signaling and induction of apoptosis.
DISCUSSION
Although erlotinib exhibits potent anti-cancer activity against human NSCLC tumors with activating mutations in EGFR, it also has activity in some patients with wild-type EGFR. It has been unclear as to what molecular mechanisms drive this sensitivity and, further, how to identify wild-type EGFR tumors that might be susceptible to erlotinib treatment. In the present study, we found that NSCLC cells harboring wild-type EGFR show varying sensitivity to erlotinib treatment that is dependent on LKB1 status. We demonstrated that erlotinib suppressed viability and enhanced apoptosis of LKB1-deficient NSCLC cells both in vitro and in vivo. Another study recently reported that glioblastoma cells with wildtype EGFR exhibited sensitivity to erlotinib treatment that was associated with inhibition of autophagy but was independent of caspase activity. 34 Consistent with this report, our findings indicate that erlotinib can be beneficial even in tumors that are not EGFR mutated. However, we show that apoptosis is elevated in erlotinib-treated cells and that the inhibitory effects of erlotinib are enhanced in tumors that have dysregulated LKB1-AMPK pathway signaling. Because this signaling pathway normally serves to maintain mitochondrial function and bioenergetic homeostasis in response to metabolic stress, we hypothesized that LKB1-deficient cells may be compromised in their ability to cope with metabolic alterations induced by erlotinib treatment.
To further examine the mechanism of erlotinib-induced apoptosis in LKB1-deficient NSCLC cells, we analyzed changes in glycolytic metabolism and mitochondrial function resulting from LKB1 knockdown. Interestingly, we observed that glucose consumption and lactate production by Calu-6 cells increased by more than 50% in response to LKB1 knockdown, which correlated with increased growth and colony formation (Figure 2c ). We also observed substantial increases in OCR (Figure 3b) and Δψ m (Figure 4a ) after expression of shLKB1 in Calu-6 and H358 cells, consistent with another recent study that profiled gene expression of over 600 patient tumors and reported upregulation of oxidative phosphorylation and mitochondriaassociated genes in samples classified as LKB1-deficient. 23 The effect of LKB1 loss to activate glycolysis and oxidative metabolism was further confirmed by expressing wild-type LKB1 in mutant A549 and H460 cell lines (Figures 2a and b, Supplementary Figures  S1 and S2) . Faubert et al. 32 previously reported simultaneous increases in both glucose uptake and lactate production in response to complete LKB1 knockout in transgenic mouse embryonic fibroblasts. They also noted enhanced flux of both glucose and glutamine into the TCA cycle of LKB1-mutant A549 cells in comparison with cells expressing wild-type LKB1, on the basis of isotope labeling experiments with 13 C-glucose and 13 Cglutamine tracers. These previous findings are consistent with our own results indicating increased dependence of LKB1-deficient cells on mitochondrial metabolism to support enhanced cell proliferation.
Despite elevated rates of oxidative metabolism, we observed only slight changes in basal ADP/ATP ratios and ROS levels in LKB1 knockdown cells (Figures 3c and 4b) . However, the effect of LKB1 depletion to alter mitochondrial function became readily apparent when shLKB1 cells were challenged with erlotinib. Substantial increases in ADP/ATP and ROS levels were observed, which were accompanied by depletion of Δψ m (Figure 4a ). In contrast, control cells were able to maintain normal ADP/ATP, ROS and Δψ m levels in response to the same concentration of erlotinib (Figures 3c, 4a  and b) . Taken together, these data provide a clear indication that LKB1 is required for maintenance of mitochondrial function in the presence of erlotinib treatment. As a result, LKB1-deficient cells cannot effectively restore ATP levels or prevent ROS accumulation in response to erlotinib, resulting in selective growth inhibition ( Figure 2 ) and apoptosis activation (Figures 4c and d) . In this context, we view the decoupling of ROS from OCR and Δψ m measurements as an indicator of mitochondrial dysfunction following erlotinib treatment. These results are similar to those reported by Shackelford et al., 12 where significant increases in ROS and decreases in Δψ m were simultaneously observed in response to phenformin treatment of LKB1-mutant A549 cells. Our results are also consistent with another previous study that showed that AMPK-deficient cells are unable to maintain sufficient NADPH levels needed to neutralize mitochondrial ROS during metabolic stress, 35 a mechanism that may further contribute to the enhanced erlotinib sensitivity we observed in LKB1-deficient cells.
Despite the previously described similarities, our observations of increased basal mitochondrial activity in LKB1-deficient cells are also partially at odds with the results of Shackelford et al.. 12 Their study showed that re-expressing wild-type LKB1 in A549 cells led to enhancements of basal OCR and Δψ m , implying reduced mitochondrial activity in the parental, LKB1-deficient cells. 12 In contrast, a more recent study by Faubert et al. 32 showed no change in OCR after re-expressing LKB1 in A549 cells and a reduction in OCR after re-expressing LKB1 in A427 cells, which are also LKB1 mutant type. Therefore, there is some variability in previous studies concerning the effects that manipulating LKB1 expression has on markers of mitochondrial activity. It is possible that these differences could be attributable to adaptation of LKB1 mutant cells to the re-expression of LKB1 over many generations. As our studies were completed within 10 passages following antibiotic selection, our results likely capture the immediate response to LKB1 re-expression in the absence of long-term adaptation.
Another unexpected outcome of our study was that LKB1-deficient cells still exhibited a robust ability to activate AMPK in response to increases in ADP/ATP ratio following erlotinib treatment. AMPK activation by adenine nucleotides involves at least three independent mechanisms: (1) increased AMPdependent phosphorylation by LKB1; (2) inhibitory effects of AMP on its dephosphorylation; and (3) allosteric activation by AMP and ADP. 36 The latter two mechanisms do not require LKB1. We also found that the ability of erlotinib to induce phosphorylation of AMPKα in LKB1-deficient cells was partially inhibited by cotreatment with either STO-609 or BAPTA-AM (Figure 5d ), indicating involvement of CaMKKβ as an alternative kinase that contributes to erlotinib-induced AMPK phosphorylation. Two prior articles have reported that AMPK phosphorylation by CaMKKβ is dependent on AMP and ADP levels. 37, 38 The large increase in ADP/ ATP ratio that we observed following erlotinib treatment could therefore be sufficient to activate AMPK even when LKB1 was depleted, possibly by a CaMKKβ-dependent mechanism. We cannot rule out, however, that changes in Ca 2+ levels may synergize with changes in energy charge to stimulate AMPK activation in response to erlotinib treatment. Consistent with this hypothesis, gefitinib has been reported to increase cytosolic and mitochondrial calcium levels of Bcl-2-overexpressing cells. 39 Erlotinib-mediated AMPKα activation led to inhibition of mTOR phosphorylation in LKB1-deficient cells, which correlated with inhibition of phosphorylated p70S6K and 4EBP-1 (Figure 5c ) as major downstream effectors of the mTOR signaling pathway. These data are consistent with the known role of AMPK to suppress mTOR signaling in response to low ATP levels, leading to inhibition of protein synthesis and proliferation of cancer cells. 10, 40 Previous studies suggested that loss of LKB1 induced increased cell size and mass due to failure of AMPK to inhibit mTOR signaling. 32, 33 In contrast, we found that only LKB1-deficient cells effectively suppressed mTOR signaling and induced PARP cleavage in response to erlotinib treatments, both in vitro and in vivo. This led to a significant decrease in growth of LKB1-deficient xenograft tumors. It is likely that mitochondrial dysfunction associated with LKB1 deficiency sensitizes cells to erlotinib treatment by enhancing changes in ADP/ATP and ROS levels, which subsequently activate AMPK and suppress mTOR signaling.
Inhibition of Erk signaling has also been shown to induce pyruvate dehydrogenase kinase 4 (PDK4) expression and redirect cellular metabolism in mammary epithilia. 41 However, we do not expect that changes in Mek/Erk signaling or PDK4 expression were directly involved in regulating the metabolic response to erlotinib treatment in our studies. First, no significant change in Erk phosphorylation was observed in response to erlotinib treatment of Calu-6 cells (Figure 5c, Supplementary Figure S4) . Second, if PDK4 expression was induced by erlotinib treatment, we would expect to see increased lactate production due to inhibition of pyruvate dehydrogenase flux. However, this was not observed in any of the cell lines tested. Finally, to confirm these observations, we performed western blot analysis with an anti-PDK4 antibody in LKB1-overexpressing and stable knockdown cell lines (Supplementary Figure S5) . No significant changes in PDK4 expression were observed after 24 h of erlotinib treatment. Taken together, we conclude that erlotinib treatment reduces OCR in LKB1-deficient cells independently of Erk and PDK4.
In conclusion, we demonstrate for the first time that erlotinib induces apoptosis in EGFR wild-type NSCLC cells by a mechanism that is enhanced by LKB1 loss of function ( Figure 7) . Although LKB1-deficient cells relied more heavily on mitochondrial oxidative phosphorylation for energy production under basal conditions, they could not properly respond to metabolic stress induced by erlotinib treatment in order to maintain energetic homeostasis. These metabolic alterations were associated with more pronounced AMPK activation and inhibition of mTOR signaling in LKB1-deficient cells, resulting in increased sensitivity to erlotinib treatment. Taken together, our findings provide a rationale for erlotinib treatment of LKB1-deficient NSCLC tumors, even in the absence of EGFR activating mutations. These tumors may constitute a distinct NSCLC molecular subtype with enhanced erlotinib sensitivity, which motivates the development of novel diagnostic approaches (for example, mRNA expression profiling 23 ) capable of identifying LKB1-deficient patient tumors that are potentially susceptible to erlotinib treatment.
MATERIALS AND METHODS
Cell culture and reagents
Human NSCLC Calu-6, H358, H2009, H460, H23, H2122, HCC15 and A549 cell lines were generously shared with us by John Minna and Luc Girard (University of Texas Southwestern Medical Center, Dallas, TX, USA). Cells were tested to ensure that they were mycoplasma negative. The human NSCLC cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS; GIBCO-BRL, Gaithersburg, MD, USA) in a humidified atmosphere with 5% CO 2 . A549 and H460 cells stably expressing either an empty pBABE vector (vector) or wild-type LKB1 (LKB1) were generated by retroviral transduction. The empty pBABE viral plasmid and pBABE-LKB1 plasmid were obtained from Addgene (Cambridge, MA, USA). Phoenix cells were transfected with viral plasmids, and retroviral particles were harvested from media supernatant 48 h after transfection. Viruses were added to target cells with polybrene, and selection with 1 μg/ml puromycin was begun 48-72 h after infection. Cells were selected under puromycin for 1-2 weeks before performing subsequent experiments, with experiments being completed within 2 months. Erlotinib (an inhibitor of EGFR), LY294002 (an inhibitor of PI3K) and rapamycin (an inhibitor of mTOR) were purchased from LC Laboratories (Woburn, MA, USA).
Cell viability analysis, colony formation assays and growth rate measurements Cells were plated in 96-well plates in complete medium and treated with various concentrations of erlotinib, LY294002 or rapamycin. Cell viability was analyzed after 2 days of treatment using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay according to the manufacturer's instructions (Sigma, St Louis, MO, USA). Cell proliferation was analyzed every 8 or 16 h for 3 days after erlotinib treatment using the CyQUANT Direct Cell Proliferation Assay according to the manufacturer's protocol (Invitrogen, Frederick, MD, USA). The fluorescence intensity was measured with a fluorescence microplate reader (Bio-Tek Instruments, Winooski, VT, USA). Conditioned medium samples were collected from each well before CyQUANT analysis, frozen, and stored for metabolite analysis. Colony formation assays were performed following treatment with 5 μM erlotinib for 3 days, at which time the cells were replated in sixwell plates at low density (1 × 10 3 cells per well) in complete medium for 2 weeks. Colonies were fixed with methanol and stained with 0.1% crystal violet (Sigma-Aldrich). Colony numbers were assessed visually and colonies measuring at least 50 μm were counted.
Metabolite analysis and oxygen consumption rate Conditioned medium samples collected during cell growth experiments were subjected to glucose and lactate analysis using a YSI 2300 biochemical analyzer (YSI Life Science, Yellow Springs, OH, USA). The ETA software package was applied to calculate specific rates of glucose consumption and lactate production using an exponential growth Figure 7 . Hypothetical schema of erlotinib-induced cell death in LKB1-deficient cells. LKB1-deficient cells exhibit enhanced mitochondrial metabolism, as indicated by increased mitochondrial potential and OCR. Erlotinib treatment selectively induces mitochondrial dysfunction in LKB1-deficient cells, decreasing mitochondrial potential and OCR while increasing ADP/ATP and ROS. This has the dual effect of inhibiting growth (via activation of AMPK and suppression of mTOR signaling) and activating apoptosis. This mechanism is based on composite data from our in vitro studies on multiple LKB1 wild-type (Calu-6, H358) and LKB1 mutant (A549, H460) cell lines, as well as in vivo data from Calu-6 mouse xenografts.
model. 42 OCR was measured using the Oxygraph-2K (Oroboros, Innsbruck, Austria), which contains two chambers with separate oxygen probes to monitor online changes in oxygen concentration. The instrument was set to a temperature of 37°C, and the stirring speed for each chamber was 750 r.p.m. After treatment with erlotinib for 24 h, cells were trypsinized, resuspended in the same culture medium at a concentration of 1-2 × 10 6 cells per ml and injected into the Oxygraph instrument.
LKB1 stable knockdown using lentiviral short-hairpin RNA For generation of stable knockdown cells, lentiviral LKB1 short-hairpin RNA (shRNA) constructs and a non-targeting shRNA control were purchased from Open Biosystems (Huntsville, AL, USA). These constructs were cloned into a pLKO.1 vector. HEK293T cells (2 × 10 6 cells) were plated on 100 mm dishes and 1 day later were co-transfected with 5 μg shRNA constructs, 3 μg pCMV-dR8.2 dvpr (Addgene) and 2 μg pCMV-VSV-G (Addgene) using a calcium phosphate transfection kit (Invitrogen). After 6 h, the medium was exchanged with fresh medium, and then the viral stock was collected for 1-2 days and filtered to remove non-adherent HEK293T cells. To obtain stable shRNA-expressing clones, Calu-6 or H358 cells were plated on sixwell plates, and 1 day later infected with 1 ml of lentiviral suspension plus 4 μg/ml polybrene. Puromycin selection (0.5-2 μg/ml) was initiated 2 days after lentiviral infection.
Western blotting
Total cell lysates were resolved using sodium dodecyl sulfatepolyacrylamide gel electrophoresis and then transferred onto polyvinylidene fluoride membranes (EMD Millipore Corporation, Billerica, MA, USA). Western blotting was performed as described previously. 43 The following antibodies were purchased from Cell Signaling (Danvers, MA, USA): rabbit polyclonal antibodies against LKB1, phosphorylated AMPKα, phosphorylated ACC, phosphorylated Tuberin/TSC2 (Ser1387), phosphorylated mTOR (Ser2448), phosphorylated 4EBP1 (Thr37/46), phosphorylated Akt (Ser473), phosphorylated Erk (Thr202/Tyr204), PARP, and mouse monoclonal antibodies against phosphorylated p70S6K (Thr389). A goat polyclonal anti-actin antibody was purchased from Santa Cruz (Santa Cruz, CA,USA). All experiments were performed in triplicate.
Flow cytometry
Cells were seeded in six-well plates containing complete medium and treated with 5 μM or 10 μM erlotinib. After 72 h, cells were harvested, pooled, and fixed with 1% paraformaldehyde and 70% ethanol. Apoptosis was assessed with flow cytometry using the Annexin V-FITC Apoptosis kit (Clontech, Mountain View, CA, USA). To measure mitochondrial ROS after 24 h of erlotinib treatment, cells were stained with MitoSOX Red (Molecular Probes, Eugene, OR, USA) for 40 min at 37°C in the dark. Annexin V and MitoSOX Red were analyzed using a LSRII flow cytometer (Becton Dickinson, San Jose, CA, USA).
Assessment of ADP/ATP ratio and mitochondrial membrane potential
Cells were seeded in 96-well plates and treated with 25 μM erlotinib for 24 h. Intracellular ADP/ATP ratio was measured using a bioluminescent ADP/ATP Ratio Assay Kit according to the manufacturer's instructions (Abcam, Cambridge, MA, USA). Mitochondrial membrane depolarization was determined using the JC-1 fluorescence probe according to the manufacturer's instructions (Molecular Probes). Cells were labeled with 2 μM JC-1 for 30 min at 37°C in the dark and then analyzed at 488 nm excitation with 530/30 or 585/42 nm bypass emission filters using a fluorescence microplate reader (Bio-TeK Instruments).
Animal experiments
The research protocol for animal studies was approved by and carried out in accordance with the Vanderbilt Institutional Animal Care & Use Committee. Female Foxn1 nu/nu nude mice aged 4-5 weeks were purchased from Harlan Laboratories (Indianapolis, IN, USA). Both non-targeting shRNA (shCon, LKB1 wild-type) and LKB1 shRNA (shLKB1, LKB1 knockdown) Calu-6 cells were injected subcutaneously into the left/right flanks at 5 × 10 6 cells per mouse mixed 1:1 with 100% growth factor-reduced Matrigel (BD Bioscience, San Jose, CA, USA). The mice were randomly assigned to shCon +vehicle solution (in sodium carboxymethylcellulose and Tween 80), shCon +erlotinib, shLKB1+ vehicle solution and shLKB1+erlotinib, with each group containing 8-10 mice. After 1 week, mice were treated with vehicle or erlotinib (100 mg/kg) daily by oral gavage for 3 weeks. Tumor size was calculated by measuring the tumors in three dimensions using calipers twice a week, 44 and body weight was measured twice weekly. On day 21, mice were euthanized and tumor tissues were harvested for pathologic examination (immunohistochemical analysis) and analyzed by western blotting.
Statistical analyses
The data acquired with MTT, colony formation and ADP/ATP assays were analyzed using the Student t-test. The Mann-Whitney U-test was used to compare differences in tumor weight. In all of the statistical analyses, twosided P-values o 0.05 were considered statistically significant.
